Biotechnology company EdiGene today announced the completion of a RMB450 million yuan in series B financing. This round of financing was led by 3H Health Investment, participated by Sequoia Capital China Fund, Yahui Investment, and Kunlun Capital. The company’s existing investors IDG Capital, Eli Lilly Asia Fund, Huagai Capital, and Pine Venture Capital also participated […]
Chinese Gene Editing Startup EdiGene Raises RMB450 Million comes from China Money Network: Primary Data for China’s Primary Markets! All Rights Reserved.